Immunitybio, Inc.

Immunitybio, Inc. company information, Employees & Contact Information

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman

Company Details

Employees
587
Address
3530 John Hopkins Ct, San Diego,ca 92121,united States
Phone
(310) 883-1300
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, CA
Looking for a particular Immunitybio, Inc. employee's phone or email?

Immunitybio, Inc. Questions

News

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Business Wire

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients Business Wire

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Yahoo Finance

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors Yahoo Finance

FDA authorizes Expanded Access Program of Anktiva for lymphopenia - Urology Times

FDA authorizes Expanded Access Program of Anktiva for lymphopenia Urology Times

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval Seeking Alpha

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Yahoo Finance

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors Yahoo Finance

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - Business Wire

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy Business Wire

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - Yahoo Finance

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID Yahoo Finance

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy - Business Wire

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy Business Wire

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device - Business Wire

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device Business Wire

ImmunityBio to Host Investor Day - Yahoo Finance

ImmunityBio to Host Investor Day Yahoo Finance

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - Business Wire

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates Business Wire

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching - Yahoo Finance

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching Yahoo Finance

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code - Business Wire

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code Business Wire

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - Business Wire

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East Business Wire

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia Business Wire

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer Business Wire

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreat - Business Wire

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreat Business Wire

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ Business Wire

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (NASDAQ:IBRX) - Seeking Alpha

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (NASDAQ:IBRX) Seeking Alpha

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum Seeking Alpha

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Yahoo Finance

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ Yahoo Finance

First commercial doses of N-803 for NMIBC administered across US - Urology Times

First commercial doses of N-803 for NMIBC administered across US Urology Times

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer - Business Wire

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer Business Wire

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer - Business Wire

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer Business Wire

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Business Wire

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Business Wire

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - PR Newswire

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment PR Newswire

ImmunityBio: Anktiva Approval Opens Possibilities, Risks And Potential Gains (NASDAQ:IBRX) - Seeking Alpha

ImmunityBio: Anktiva Approval Opens Possibilities, Risks And Potential Gains (NASDAQ:IBRX) Seeking Alpha

ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities - Business Wire

ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities Business Wire

ImmunityBio announces promising clinical study results for ‘kick and kill’ HIV cure strategy to reduce HIV viral load with Anktiva (N-803) therapy - European AIDS Treatment Group

ImmunityBio announces promising clinical study results for ‘kick and kill’ HIV cure strategy to reduce HIV viral load with Anktiva (N-803) therapy European AIDS Treatment Group

Australian Biotech EnGeneIC Strikes Landmark Deal with - GlobeNewswire

Australian Biotech EnGeneIC Strikes Landmark Deal with GlobeNewswire

Top Immunitybio, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant